Inflammatory markers and control of type 2 diabetes mellitus

Elimam, Hanan; Abdulla, Azza M.; Taha, Inass M.

doi:10.1016/j.dsx.2018.11.061

Cited by 76 publications

(58 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We observed that the expression of miR‐146a was diminished in pre‐diabetic individuals, which is consistent with previous studies . Also, miR‐146a relative expression was associated with C‐reactive protein (an inflammatory marker) only in the T2D patients’ group. This specific miR‐146a expression behaviour might be related to the activation of the promoter of miR‐146a by inflammatory cytokines .…”

Section: Resultssupporting

confidence: 91%

Circulating miR‐146a, miR‐34a and miR‐375 in type 2 diabetes patients, pre‐diabetic and normal‐glycaemic individuals in relation to β‐cell function, insulin resistance and metabolic parameters

García-Jacobo

Uresti-Rivera

Portales-Pérez

et al. 2019

Clin Exp Pharma Physio

View full text Add to dashboard Cite

The pathogenesis of type 2 diabetes (T2D) is associated with a progressive loss of pancreatic β-cell mass. It is known that miR-146a, miR-34a, and miR-375 are involved in β-cell functionality. In this work, we evaluated the levels of these miRNAs in normal-glycaemic individuals, pre-diabetic, and T2D patients in relation to β-cell functionality, insulin resistance, and metabolic parameters. The relative expression of the miRNAs was evaluated in serum samples by real-time polymerase chain reaction. In a principal component analysis, we observed that T2D patients and pre-diabetic individuals were not associated with β-cell functionality. However, in a correlation matrix analysis, we detected that miR-34a was related to miR-146a and insulin resistance.The relative expression of miR-375 was correlated with cholesterol and low-density lipoprotein levels. A decrease of β-cell function in pre-diabetic individuals and T2D patients was observed. The insulin resistance was higher in pre-diabetic individuals and T2D patients. The relative expression of miR-146a in pre-diabetic individuals, T2D patients with insulin treatment, and T2D patients with nephropathy and diabetic foot was decreased. In addition, miR-34a was increased in T2D patients who were overweight and obese. The relative expression of miR-375 was increased in T2D patients with poor glycaemic control, while a decrease was seen in T2D patients with nephropathy and diabetic foot. Circulating miR-375, miR-34a, and miR-146a were not associated with β-cell functionality, but their expression was differentially affected by glycaemia, obesity, insulin treatment, and the presence of nephropathy and diabetic foot. K E Y W O R D Sdiabetic foot, glycaemia, insulin treatment, nephropathy, obesity | 1093 GARCÍA-JACOBO et Al.

show abstract

Section: Resultssupporting

confidence: 91%

Circulating miR‐146a, miR‐34a and miR‐375 in type 2 diabetes patients, pre‐diabetic and normal‐glycaemic individuals in relation to β‐cell function, insulin resistance and metabolic parameters

García-Jacobo

Uresti-Rivera

Portales-Pérez

et al. 2019

Clin Exp Pharma Physio

View full text Add to dashboard Cite

show abstract

“…Generally used to refer to the patients' level of glycemic control, the HbA1c >7 in all our patients is in fact an indication of glycemic imbalance similar to that reported in the literature. We also found a significant positive association between hsCRP and HbA1c (r=0.18, p=0.042), though poorer than in other studies involving diabetics and non-diabetics [23]. The degree of glycemic imbalance did not seem to affect that of subclinical inflammation according to our data (table 3), unlike in other studies where the poorer the glycemic control, the higher the level of hsCRP [24].…”

Section: Inflammation Assessmentcontrasting

confidence: 48%

The Inflammatory Marker HSCRP as a Predictor of Increased Insulin Resistance in Type 2 Diabetics without Atherosclerotic Manifestations

Grigorescu¹,

Șorodoc²,

Floria³

et al. 2019

Rev. Chim.

View full text Add to dashboard Cite

Low-grade inflammation is not only a specific feature in type 2 diabetes mellitus, but also a contributor to cardiovascular risk. Together with insulin resistance as the main characteristic of type 2 diabetes mellitus, subclinical imflammation maintains a vicious cycle of health-damaging processes. Our study assessed the inflammatory marker hsCRP in relation to the metabolic profiles of type 2 diabetic patients without clinical atherosclerotic manifestations. The results confirmed the hypothesized connection, which should be taken into consideration when designing and recommending diabetes care plans.

show abstract

“…Chronic inflammation is considered as an essential etiological factor in the development of hepatic insulin resistance (Elimam, Abdulla, & Taha, 2019). Patients with T2DM and animal models with insulin resistance often exhibit elevation of proinflammatory cytokines in hepatic and adipose tissues, including IL‐1β, IL‐6, and TNF‐α, which participate in and mediate inflammatory response (Jin et al., 2019).…”

Section: Resultsmentioning

confidence: 99%

Beneficial effects of Aronia melanocarpa berry extract on hepatic insulin resistance in type 2 diabetes mellitus rats

Xin

Zhang

et al. 2020

Journal of Food Science

View full text Add to dashboard Cite

We aimed to investigate) the effects of Aronia melanocarpa berry extract (AMBE) on hepatic insulin resistance and its mechanism at the molecular level in high-fat diet (HFD)-and streptozotocin (STZ)-induced type 2 diabetes mellitus (T2DM) rats. The rats were supplemented with AMBE at doses of 100 and 400 mg/kg body weight (bw) daily for 8 weeks. AMBE significantly reduced blood glucose and serum insulin levels and the homeostatic model assessment for insulin resistance score; improved glucose tolerance; increased hepatic glycogen content; and regulated glucose metabolism enzyme activity, including glucokinase, pyruvate kinase, phosphoenolpyruvate carboxykinase, and glucose-6-phosphatase in the liver. AMBE also reduced lipid accumulation and oxidative stress along with inflammation in the hepatic tissue of T2DM rats and improved hepatic function. The phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway was activated by AMBE through the elevation of insulin receptor substrate-2, PI3K, Akt, and glycogen synthase kinase-3β phosphorylation and glucose transporter 2, which might contribute to the promotion of glycogen synthesis and improvement of hepatic insulin resistance. AMBE shows promise as an ingredient of functional foods for alleviating hepatic insulin resistance in T2DM.Keywords: Aronia melanocarpa berry, hepatic insulin resistance, PI3K/Akt signaling pathway, type 2 diabetes mellitus Practical Application: The extract from the berries of Aronia melanocarpa (Michx.) Elliott (AMBE), with its relatively high content of polyphenolic compounds, has been shown to exert hypoglycemic effects in animal models of diabetes. Our findings support the use of A. melanocarpa as a functional food additive for the alleviation of hepatic insulin resistance and the management of glucose homeostasis in T2DM.

show abstract

Inflammatory markers and control of type 2 diabetes mellitus

Cited by 76 publications

References 16 publications

Circulating miR‐146a, miR‐34a and miR‐375 in type 2 diabetes patients, pre‐diabetic and normal‐glycaemic individuals in relation to β‐cell function, insulin resistance and metabolic parameters

Circulating miR‐146a, miR‐34a and miR‐375 in type 2 diabetes patients, pre‐diabetic and normal‐glycaemic individuals in relation to β‐cell function, insulin resistance and metabolic parameters

The Inflammatory Marker HSCRP as a Predictor of Increased Insulin Resistance in Type 2 Diabetics without Atherosclerotic Manifestations

Beneficial effects of Aronia melanocarpa berry extract on hepatic insulin resistance in type 2 diabetes mellitus rats

Contact Info

Product

Resources

About